Challenges of CAR- and TCR-T cell-based therapy for chronic infections

J Exp Med. 2020 May 4;217(5):e20191663. doi: 10.1084/jem.20191663.

Abstract

While therapy with T cells engineered with a chimeric antigen receptor (CAR) or a classical T cell receptor (TCR) is revolutionizing cancer treatment, its adoption in infectious diseases has been met with considerable resistance. Can we find its value for the cure of infections?

Publication types

  • Review

MeSH terms

  • Animals
  • Chronic Disease
  • Humans
  • Immunotherapy*
  • Infections / immunology*
  • Infections / therapy*
  • Receptors, Antigen, T-Cell / immunology*
  • Receptors, Chimeric Antigen / immunology*
  • T-Lymphocytes / immunology*

Substances

  • Receptors, Antigen, T-Cell
  • Receptors, Chimeric Antigen